OrthoPediatrics Corp. (KIDS)
| Market Cap | 829.27M +102.0% |
| Revenue (ttm) | 264.14M +16.1% |
| Net Income | -33.88M |
| EPS | -1.42 |
| Shares Out | 26.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,976 |
| Open | 31.57 |
| Previous Close | 32.22 |
| Day's Range | 31.05 - 31.97 |
| 52-Week Range | 14.42 - 34.53 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 30.75 (-3.18%) |
| Earnings Date | Oct 27, 2026 |
About KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruct... [Read more]
Financial Performance
In 2025, OrthoPediatrics's revenue was $236.35 million, an increase of 15.45% compared to the previous year's $204.73 million. Losses were -$39.65 million, 4.83% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KIDS stock is "Buy." The 12-month stock price target is $30.75, which is a decrease of -3.18% from the latest price.
News
OrthoPediatrics to Participate in Upcoming Conferences
WARSAW, Ind., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics price target raised to $28 from $22 at Truist
Truist raised the firm’s price target on OrthoPediatrics (KIDS) to $28 from $22 and keeps a Hold rating on the shares. The company’s 19% revenue growth exceeded estimates as outperformance…
OrthoPediatrics price target raised to $28 from $23 at TD Cowen
TD Cowen raised the firm’s price target on OrthoPediatrics (KIDS) to $28 from $23 and keeps a Buy rating on the shares. The firm updated its model following a solid…
OrthoPediatrics price target raised to $38 from $34 at Lake Street
Lake Street analyst Ben Haynor raised the firm’s price target on OrthoPediatrics (KIDS) to $38 from $34 and keeps a Buy rating on the shares. Q3 results were “mixed on…
OrthoPediatrics price target raised to $30 from $28 at Canaccord
Canaccord analyst Caitlin Roberts raised the firm’s price target on OrthoPediatrics (KIDS) to $30 from $28 and keeps a Buy rating on the shares. The firm said the company KIDS…
OrthoPediatrics price target raised to $30 from $25 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on OrthoPediatrics (KIDS) to $30 from $25 and keeps an Overweight rating on the shares. The firm notes the company…
OrthoPediatrics price target raised to $27 from $24 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on OrthoPediatrics (KIDS) to $27 from $24 and keeps a Buy rating on the shares.
OrthoPediatrics price target raised to $30 from $29 at BTIG
BTIG raised the firm’s price target on OrthoPediatrics (KIDS) to $30 from $29 and keeps a Buy rating on the shares. The firm cites the company’s Q3 revenue beat and…
OrthoPediatrics receives FDA clearance for pediatric femur retrograde nail
OrthoPediatrics (KIDS) announced U.S. Food and Drug Administration clearance of the Pediatric Nailing Platform Femur Retrograde Nail System and the successful completion of the first procedures using ...
OrthoPediatrics reports Q3 EPS (23c), consensus (22c)
Reports Q3 revenue $72.66M, consensus $68.5M. “In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and…
OrthoPediatrics Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $72.7M, up 19%, with adjusted EBITDA of $6.9M and positive free cash flow. FY26 revenue guidance rose to $270M–$273M as early product launches and strong OPSB momentum support growth, with broader Super Cycle impact expected from 2027.
OrthoPediatrics Earnings release: Q3 2026
OrthoPediatrics released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
OrthoPediatrics Quarterly report: Q3 2026
OrthoPediatrics has published its Q3 2026 quarterly earnings report on October 27, 2026.
OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance
Record Third Quarter 2026 Revenue of $72.7 Million , Up 19% Year-over-Year
OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations
New addition to the Pediatric Nailing Platform expands options for pediatric femoral trauma and deformity correction New addition to the Pediatric Nailing Platform expands options for pediatric femora...
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026
WARSAW, Ind., Oct. 13, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX
WARSAW, Ind., Oct. 07, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course
Milestone program with record attendance brought together 39 participants from 23 institutions across 22 cities and three countries Milestone program with record attendance brought together 39 partici...
OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Techn...
OrthoPediatrics price target raised to $29 from $24 at BTIG
BTIG raised the firm’s price target on OrthoPediatrics (KIDS) to $29 from $24 and keeps a Buy rating on the shares as part of a broader research note updating the…
OrthoPediatrics Transcript: Canaccord Genuity's 46th Annual Growth Conference
Record Q2 results and raised guidance highlight a pivotal inflection point, driven by innovative product launches, improved asset utilization, and strong international growth. The business is set for continued profitability, with a robust pipeline and favorable competitive dynamics.
OrthoPediatrics price target raised to $22 from $20 at Truist
Truist analyst Richard Newitter raised the firm’s price target on OrthoPediatrics (KIDS) to $22 from $20 and keeps a Hold rating on the shares. OrthoPediatrics delivered a strong Q2 beat…
OrthoPediatrics price target raised to $25 from $22 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on OrthoPediatrics (KIDS) to $25 from $22 and keeps an Overweight rating on the shares. The firm notes the company…
OrthoPediatrics price target raised to $28 from $25 at Canaccord
Canaccord raised the firm’s price target on OrthoPediatrics (KIDS) to $28 from $25 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 revenue…